Patents by Inventor Sonke Svenson
Sonke Svenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170325457Abstract: The present disclosure is directed to formulations comprising (1) at least one formulation transport agent, (2) at least one complexing agent, and (3) at least one active agent that modulates one or more traits of a target insect, plant, or plant pathogen. The present disclosure is also directed to methods of delivering such formulations to the target organism, as well as to formulation transport agents used to prepare such formulations.Type: ApplicationFiled: April 26, 2017Publication date: November 16, 2017Applicant: Preceres Inc.Inventors: Richard Wayne Heidebrecht, JR., Sonke Svenson, Roger Wiegand, Jungyeon Hwang, Jen Beaudoin, Cheng Zhong
-
Publication number: 20160058873Abstract: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.Type: ApplicationFiled: March 23, 2015Publication date: March 3, 2016Inventors: Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Cissy Young
-
Publication number: 20150209440Abstract: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.Type: ApplicationFiled: April 9, 2015Publication date: July 30, 2015Applicant: CERULEAN PHARMA INC.Inventors: Scott Eliasof, Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Donald E. Bergstrom
-
Publication number: 20140296322Abstract: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.Type: ApplicationFiled: April 18, 2014Publication date: October 2, 2014Applicant: CERULEAN PHARMA INC.Inventors: Scott Eliasof, Oliver S. Fetzer, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Jungyeon Hwang, Donald Bergstrom
-
Publication number: 20140213504Abstract: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.Type: ApplicationFiled: November 25, 2013Publication date: July 31, 2014Applicant: Cerulean Pharma Inc.Inventors: Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Cissy Young
-
Publication number: 20140135254Abstract: Described herein are conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, which can be used, for example, in the treatment of a disorder such as cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of making the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: March 28, 2013Publication date: May 15, 2014Applicant: CERULEAN PHARMA INC.Inventors: Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson
-
Publication number: 20140037573Abstract: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.Type: ApplicationFiled: February 21, 2013Publication date: February 6, 2014Inventors: Scott Eliasof, Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Donald Bergstrom
-
Publication number: 20120302505Abstract: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.Type: ApplicationFiled: April 20, 2012Publication date: November 29, 2012Inventors: Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Cissy Young
-
Publication number: 20120302622Abstract: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.Type: ApplicationFiled: April 10, 2012Publication date: November 29, 2012Applicant: CERULEAN PHARMA INC.Inventors: Scott Eliasof, Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Donald E. Bergstrom
-
Publication number: 20120225129Abstract: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.Type: ApplicationFiled: August 18, 2011Publication date: September 6, 2012Applicant: CERULEAN PHARMA INC.Inventors: Scott Eliasof, Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Donald E. Bergstrom
-
Publication number: 20120052097Abstract: Described herein are conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, which can be used, for example, in the treatment of a disorder such as cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of making the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: August 18, 2011Publication date: March 1, 2012Applicant: Cerulean Pharma Inc.Inventors: Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson
-
Patent number: 7985424Abstract: Dendritic polymers with enhanced amplification and interior functionality are disclosed. These dendritic polymers are made by use of fast, reactive ring-opening chemistry (or other fast reactions) combined with the use of branch cell reagents in a controlled way to rapidly and precisely build dendritic structures, generation by generation, with cleaner chemistry, often single products, lower excesses of reagents, lower levels of dilution, higher capacity method, more easily scaled to commercial dimensions, new ranges of materials, and lower cost. The dendritic compositions prepared have novel internal functionality, greater stability (e.g., thermal stability and less or no reverse Michael's reaction), and reach encapsulation surface densities at lower generations. Unexpectedly, these reactions of polyfunctional branch cell reagents with polyfunctional cores do not create cross-linked materials.Type: GrantFiled: December 21, 2005Date of Patent: July 26, 2011Assignee: Dendritic Nanotechnologies Inc.Inventors: Donald A. Tomalia, Douglas R. Swanson, Baohua Huang, Veera Reddy Pulgam, Joseph R. Heinzelmann, Sonke Svenson, Lori A. Reyna, Michael A. Zhuravel, Abhay Singh Chauhan, Cordell R. DeMattei
-
Publication number: 20090324742Abstract: The present invention concerns poly(etherhydroxylamine) PEHAM dendritic polymers wherein they function as excipients for the enhancement of water solubility of poorly water soluble (hydrophobic) Active Materials or enhancement of oil solubility of poorly oil soluble (hydrophilic) Active Materials. These dendritic polymers can have Active Materials associated with them by one or more of the following: (a) by adsorption onto the surface or (b) encapsulation into the interior of the dendritic polymers or (c) a mixture of both where these interactions are driven by one or more of the following (i) electrostatic attraction, (ii) hydrogen bonding between dendritic polymers and Active Material and (iii) hydrophobic or hydrophilic interactions or mixtures of these interactions. Additionally, these associated Active Materials can be associated with dendritic polymers through chemical bonding to the surface or to internal functionalities (IF) of PEHAM dendritic polymers or both.Type: ApplicationFiled: September 7, 2007Publication date: December 31, 2009Inventors: Sonke Svenson, Abhay Singh Chauhan
-
Publication number: 20090012033Abstract: The present invention concerns core-shell tecto (dendritic polymers) that are associated with biologically active materials (such as nucleic acids for use for RNAi and in transfection). Also included are formulations for their use. The constructs are useful for the delivery of drugs to an animal or plant and may be in vivo, in vitro or ex vivo.Type: ApplicationFiled: March 3, 2007Publication date: January 8, 2009Inventors: Cordell R. DeMattei, Baohua Huang, Lori A. Reyna, Sonke Svenson, Douglas R. Swanson, Donald A. Tomalia, Michael A. Zhuravel, Veera Reddy Pulgam
-
Publication number: 20070298006Abstract: Dendritic polymers with enhanced amplification and interior functionality are disclosed. These dendritic polymers are made by use of fast, reactive ring-opening chemistry (or other fast reactions) combined with the use of branch cell reagents in a controlled way to rapidly and precisely build dendritic structures, generation by generation, with cleaner chemistry, often single products, lower excesses of reagents, lower levels of dilution, higher capacity method, more easily scaled to commercial dimensions, new ranges of materials, and lower cost. The dendritic compositions prepared have novel internal functionality, greater stability (e.g., thermal stability and less or no reverse Michael's reaction), and reach encapsulation surface densities at lower generations. Unexpectedly, these reactions of polyfunctional branch cell reagents with polyfunctional cores do not create cross-linked materials.Type: ApplicationFiled: December 21, 2005Publication date: December 27, 2007Applicant: Dendritic Nanotechnologies, Inc.Inventors: Donald Tomalia, Douglas Swanson, Baohua Huang, Veera Pulgam, Sonke Svenson, Lori Reyna, Michael Zhuravel, Abhay Chauhan, Cordell DeMattei, Joseph Heinzelmann
-
Publication number: 20040028747Abstract: Drug particles which are essentially crystalline and have a mean particle size below about 2 microns, when dispersed in water, are described. When added to an aqueous medium at 25-95% of the equilibrium solubility of the drug substance, the drug particles show complete dissolution, as characterized by a 95% reduction in turbidity, in less than 5 minutes. Using a controlled precipitation process to prepare such drug particles is also described. Such drug particles exhibit an enhanced dissolution rate and better stability as compared to particles prepared according to processes described in the prior art.Type: ApplicationFiled: August 6, 2002Publication date: February 12, 2004Inventors: Christopher J. Tucker, Sonke Svenson, James E. Hitt, Cathy A. Curtis
-
Publication number: 20040028746Abstract: Particles having a plurality of crystalline domains are described. Each crystalline domain is oriented differently than any of the adjacent domains and comprises a drug substance. A plurality of interfacial regions surround the crystalline domains, each interfacial region comprising at least one stabilizer. A process used to prepare the particles of the present invention is also described. The particles of the present invention exhibit relatively fast dissolution times as compared to particles prepared by processes described in the prior art.Type: ApplicationFiled: August 6, 2002Publication date: February 12, 2004Inventors: Sonke Svenson, Christopher J. Tucker, James E. Hitt
-
Publication number: 20030133987Abstract: A method for producing micron-sized or submicron-sized drugs is disclosed, which comprises preparing a template emulsion comprising water and a templating agent; preparing a drug-containing mixture comprising a drug substance; and combining the template emulsion with the drug-containing mixture to form a template emulsion loaded with drug particles. Drug particles prepared from this process are also disclosed. The resulting drug particles demonstrate faster dissolution rates and enhanced bioavailability as compared to unprocessed drug particles and particles prepared using other processes.Type: ApplicationFiled: January 10, 2003Publication date: July 17, 2003Inventors: Sonke Svenson, Chris J. Tucker, Steve Lubetkin, Jonathan C. Evans, Steve S. Rosenberg
-
Publication number: 20030049323Abstract: A process for preparing crystalline particles of a drug substance is disclosed, said process comprising recirculating an anti-solvent through a mixing zone, dissolving the drug substance in a solvent to form a solution, adding the solution to the mixing zone to form a particle slurry in the anti-solvent, and recirculating at least a portion of the particle slurry back through the mixing zone. Particles produced from the process are also disclosed. The present invention has the ability to be operated in a continuous fashion, resulting in a more efficient process and a more uniform product. The present invention has the additional advantage of having the ability to operate at a relatively low solvent ratio, thereby increasing the drug to excipient ratio.Type: ApplicationFiled: August 27, 2002Publication date: March 13, 2003Inventors: James E. Hitt, Christopher J. Tucker, Jonathan C. Evans, Cathy A. Curtis, Sonke Svenson